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Abstract
The B cell-activating factor from the tumor necrosis factor family (BAFF) is an important regulator
of B cell immunity. Recently, we demonstrated that recombinant BAFF also provides a co-
stimulatory signal to T cells. Here, we studied expression of BAFF in peripheral blood leukocytes
and correlated this expression with BAFF T cell co-stimulatory function. BAFF is produced by
antigen-presenting cells (APC). Blood dendritic cells (DC) as well as DC differentiated in vitro from
monocytes or CD34+ stem cells express BAFF mRNA. Exposure to bacterial products further up-
regulates BAFF production in these cells. A low level of BAFF transcription, up-regulated upon
TCR stimulation, was also detected in T cells. Functionally, blockade of endogenous BAFF
produced by APC and, to a lesser extent, by T cells inhibits T cell activation. Altogether, this
indicates that BAFF may regulate T cell immunity during APC±T cell interactions and as an
autocrine factor once T cells have detached from the APC.
Introduction
The B cell-activating factor from the tumor necrosis factor
(TNF) family, BAFF (also called BLyS, TALL-1, zTNF-4 and
THANK), is a member of the TNF superfamily (1±3). BAFF
regulates B cell immunity. At a resting state, recombinant
BAFF induces the survival (4) and maturation of B cells (5).
Upon activation, BAFF decreases activation-induced cell
death in stimulated B cells (6). BAFF also stimulates T cells
by delivering co-stimulation to TCR-dependent signals (7).
The B cell immuno-stimulatory activity of BAFF has been
further observed in vivo. Injection of recombinant BAFF into
mice results in an enhancement of the pool of peripheral B cells
(3) and humoral immune responses (6). Blockade of BAFF with
a soluble form of one of its receptors inhibits production of
speci®c antibodies (8,9) and development of autoimmune
manifestations (9±11). The T cell immuno-stimulatory activity of
BAFF has been also observed in vivo. Indeed, a soluble form
of a BAFF receptor was found to inhibit T cell priming upon
antigenic challenge, although an indirect role of B cells could
not be excluded in this report (11).
Expression of BAFF was originally studied at the mRNA level
by northern blot analysis. A predominant expression in
lymphoid tissues (spleen, lymph nodes and bone marrow)
and peripheral blood was shown (1,3,12). These studies were
further re®ned, and abundant expression in myeloid cells and
granulocyte colony stimulating factor-treated neutrophils was
reported (13±15). In this study, we have further characterized
the expression of BAFF at the mRNA and protein levels in
antigen-presenting cells (APC) and T cells, and show that
endogenous production of BAFF is able to mediate T cell co-
stimulation.
Methods
Cells
Peripheral blood mononuclear cells (PBMC) were obtained
from healthy donors after Ficoll-Paque centrifugation. Cell
subsets were puri®ed by immunomagnetic procedures
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(Dynal, Oslo, Norway). For T cells, we depleted PBMC with an
anti-CD19 (J4.119; Immunotech, Marseille, France), an anti-
CD14 (RMO 52; Immunotech), an anti-MHC class II (IVA12;
ATCC, Manassas, VA) and an anti-CD56 antibody (B159;
PharMingen, San Diego, CA). For monocytes, we depleted
PBMC with the anti-CD56, the anti-CD19 and an anti-CD2
antibody (XC3, kindly provided by Dr F. Triebel, Chatenay
Malabry, France). NK cells and B cells were positively puri®ed
from total PBMC with the anti-CD56 and the anti-CD19
antibody respectively. Puri®ed activated CD4+ and CD8+ T
cells were obtained by stimulating total PBMC with phytohe-
magglutinin (PHA) for 4 days, and FACS-sorting the relevant
subpopulation following staining with an anti-CD4 and an anti-
CD8 respectively. Purity of the different cellular preparations
was 95% or more as assessed by immunostaining and ¯ow
cytometry analysis. Dendritic cells (DC) were obtained from
puri®ed monocytes cultured for 5±7 days with granulocyte
macrophage colony stimulating factor (GM-CSF; 50 ng/ml)
and IL-4 (100 U/ml) kindly provided by Dr C. Caux (Schering
Plough, Dardilly, France). DC derived from CD34+ stem cells
were generated as originally described (16). Brie¯y, CD34+
cells were puri®ed from cord blood using anti-CD34 M450
Dynabeads and Detach-a-Bead (Dynal). The cells were then
ampli®ed using an hematopoietin cocktail composed of Flt3-L,
thrombopoietin and stem cell factor for a minimum of 6 days,
and differentiated in DC with GM-CSF and IL-4 for 5 days.
Human T cell clones were generated from FACS-sorted CD3+
blood T cells stimulated with PHA and irradiated allogeneic
feeder cells. To avoid the presence of feeder cells in the
samples, they were used 2 weeks after the last in vitro re-
stimulation. Blood DC were puri®ed according to O'Doherty
et al. (17). PBMC were labeled with FITC-conjugated anti-CD3
(Dako, Zug, Switzerland), anti-CD14 (M5e2; PharMingen),
anti-CD16 (3G8; PharMingen) and anti-CD19 (HIB19;
PharMingen), phycoerythrin-conjugated anti-CD4 (RPA-T4;
PharMingen), and Cy5-conjugated anti-MHC class II (G46-6;
PharMingen). Cells harboring a high forward scatter and a low
level of CD4 expression were ®rst gated. A second gating was
performed on cells expressing MHC class II with an absence
of expression of the lineage-speci®c markers CD3, CD14,
CD16 and CD19 (gate R2). The puri®cation was performed by
FACS (FACS Vantage SE; Becton Dickinson, Mountain View,
CA).
Reagents
The rat mAb speci®c for huBAFF Buffy-2 and the mouse mAb
speci®c for APRIL aprily-1 were obtained from Apotech
(Epalinges, Switzerland). These mAb were produced against
recombinant soluble BAFF (amino acids 83±285) and APRIL
(amino acids 93±233) respectively. The rabbit polyclonal
antiserum against BAFF (CT) was purchased from Prosci
(Poway, CA). This polyclonal antiserum was produced against
the peptide 254±269 of huBAFF. Soluble recombinant huTNF
(amino acids 88±223), huBCMA (B cell maturation antigen)±Ig
(amino acids 2±54), muBAFF-R±Ig (amino acids 2±70),
huTACI (transmembrane activator and CAML interactor)±Ig
(amino acids 2±118) and muFn14±Ig (amino acids 1±75) were
obtained from Apotech. A soluble form of huCD40L was
obtained by fusing its extracellular portion (amino acids 116±
261) to the adipocyte complement-related protein of 30 kDa
(ACRP30, amino acids 18±111) as recently reported (18). Prior
to cell stimulation assays, endotoxin levels of the puri®ed
molecules were veri®ed to be <0.1 ng/mg of puri®ed proteins
as assessed with the QCL-1000 kit according to the manu-
facturer's instructions (Biowhittaker, Walkersville, MD). IFN-g
was purchased form R & D Systems (Minneapolis, MN).
Lipopolysaccharide (LPS) from Salmonella abortus-equi,
lipoteichoic acid (LTA) and puri®ed huIgG1 were purchased
from Sigma (St Louis, MO).
Gene expression analysis
Total RNA was prepared from cells using TRIzol (Gibco/BRL,
Life Technology, Basel, Switzerland). Total RNA (25 ng) was
reverse transcribed and ampli®ed using a One-Step RT-PCR
kit (Qiagen, Basel, Switzerland). Two different primer pairs
were used to detect BAFF mRNA. Primer pair A consisted of
the forward primer 5¢-ggagaaggcaactccagtcagaac-3¢ and the
reverse primer 5¢-caattcatccccaaagacatggac-3¢. Primer pair
B consisted of 5¢-gctccaggagaaggcaactc-3¢ as forward
primer and 5¢-cagcagtttcaatgcaccaa-3¢ as reverse primer.
For APRIL, 5¢- tctcagttgccctctggttg-3¢ and 5¢- gagtctcctgcctt-
ccttgg-3¢ were used as forward and reverse primers respect-
ively. The control actin primers were forward 5-ttaacga-
gaagctgtgctacgtc-3¢and reverse 5¢-atagtcctgcttgcttgctgatc-
cac-3¢. Denaturation was performed at 94°C for 1 min,
annealing at 55°C for 1 min and extension at 72°C for 1 min.
Forty cycles were applied for non-quantitative studies.
Ampli®ed mRNAs were visualized on agarose gels and
ethidium bromide staining. To exclude ampli®cation of
genomic DNA, all the primers used in this study spanned
intronic sequences on the genomic DNA. Speci®city of the
ampli®cations was checked by restriction analysis with three
selected enzymes for each primer pair. For semi-quantitative
analysis, the reaction was not performed to saturation by
applying <40 cycles.
For blood DC, 2000 cells were FACS sorted in duplicate
wells of 96 V-bottomed plates. Cells were lysed and cDNA was
synthesized with the MMLV reverse transcriptase reaction kit
(Gibco/BRL) in 0.12% Triton X-100 with 80 U/ml of RNAsin, 200
ng/ml of oligo-dT, 50 nM of dNTP and 3 mg of tRNA for 1 h at
37°C. A standard PCR was performed on the cDNA obtained.
The purity of blood DC was veri®ed with the CD3e-speci®c
primers 5¢-aacataggcggtgatgaggatg-3¢ (forward) and 5¢-
ctcctcgtgtcacaggct tg-3¢ (reverse) as well as CD14-speci®c
primers 5¢-agctcagaggttcggaagactta-3¢ (forward) and 5¢-
atctccacctctactgcagacaca-3¢ (reverse).
For quantitative real-time PCR, total RNA was puri®ed from
105 cells using the RNeasy kit from Qiagen. cDNA were
synthesized with 60 U of reverse transcriptase and 40 ng of
oligo-dT. The quantitative PCR was performed on the cDNA
obtained with the LightCycler System (Roche Diagnostics,
Rotkreuz, Switzerland) in microcapillary tubes in QuantiTect
SYBR Green PCR kit solution (Qiagen). After a 10-min
denaturation step at 95°C, 50 PCR cycles of 15 s at 95°C, 20
s at 55°C and 60 s at 72°C were performed. To con®rm the
purity and speci®city of the reaction, a melting curve analysis
was performed at the end of the PCR by slowly increasing
(0.1°C/s) the temperature of the reaction from 65 to 95°C. The
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RT-PCR products were also analyzed by gel electrophoresis.
A standard curve was established with pure cDNA product.
The results are expressed in arbitrary units according to each
standard dilution curve where 106 U is equivalent to ~15 pg of
puri®ed cDNA. Actin ampli®cation was used as an internal
reference.
Cell lysis, immunoprecipitation, SDS±PAGE and western
blotting
Lysates were prepared from cells with 1% Triton X-100 lysis
buffer containing 10 mM sodium phosphate, 1 mM EDTA, 1
mM EGTA, 1 mM NaF, 150 mM NaCl, 10 mg/ml trypsin
inhibitor, 20 mM iodoacetamide, 0.1% NaDOC and 1 mM
PMSF. To remove nuclei, lysates were spun at 10,000 g for 5
min at 4°C. The lysates were run on SDS±PAGE gels, blotted,
and subjected to immunodetection with the indicated anti-
bodies and an ECL detection kit.
Cell supernatants were ®rst pre-cleared with Protein A±
Sepharose and then subjected to immunoprecipitation with 1
mg BCMA±Ig and Protein A±Sepharose. Beads were washed
twice in PBS and immunoprecipitated materials were eluted
with 2.5 mM glycine, HCl, pH 2.5 for 10 min. Eluted materials
were neutralized with Tris buffer, run on SDS±PAGE gels and
analyzed by western blot.
T cell proliferation assay
A T cell activation assay was performed with plastic-bound
anti-CD3 (OKT3; ATCC). Brie¯y, anti-CD3 was adsorbed to
plastic for 4 h at 37°C in PBS. Wells were washed twice with
PBS. Cells were added in RPMI 1640 supplemented with
sodium pyruvate, glutamine, HEPES and 10% heat-inactivated
FCS. Proliferation was assessed after 72 h by [3H]thymidine
incorporation for the last 18 h.
Results
BAFF is expressed in T cells and DC
We studied expression of BAFF in subsets of peripheral blood
leukocytes at the mRNA level. By RT-PCR analysis, we
detected BAFF mRNA in DC derived from monocytes and
from CD34+ cells, and in both of these DC precursors (Fig. 1A).
BAFF expression was also found in T cells, albeit at a lower
level than in DC. BAFF mRNA was only marginally expressed
in NK cells and undetectable in B cells (Fig. 1A). When T cell
subsets were further analyzed, we found BAFF mRNA in PHA-
stimulated CD4 helper as well as CD8 cytotoxic T cells
(Fig. 1A). To ascertain the expression of BAFF in T cells, we
assessed BAFF mRNA expression in long-term culture of T cell
clones. Figure 1(B) shows that the three T cell clones tested
expressed BAFF mRNA. In these samples, no message for
CD14 was detected by RT-PCR analysis (data not shown),
excluding the presence of contaminating monocytes in the
sample analyzed. Expression of BAFF mRNA in DC was
con®rmed with ex vivo DC puri®ed from peripheral blood.
Circulating DC were puri®ed from blood cells harboring a high
forward scatter and a low level of CD4 expression (gate R1,
Fig. 1C), and expressing MHC class II with an absence of
expression of the lineage-speci®c markers CD3, CD14, CD16
and CD19 (gate R2, Fig. 1C). RT-PCR analysis of these blood
DC shows BAFF mRNA expression (Fig. 1C, right panel). In
this blood DC preparation, no message for CD14 and CD3
was found (data not shown), excluding the presence of
monocytes and T cells. The BAFF expression in T cells and DC
shown here was obtained with a second pair of BAFF-speci®c
primers (primer pair B; data not shown). Altogether, these
Fig. 1. BAFF gene expression in peripheral blood leukocytes. RNA
from the indicated cell subsets were extracted and subjected to RT-
PCR (40 cycles) with a BAFF-speci®c primer pair. (A) BAFF mRNA
was detected in CD3+ T cells, CD14+ monocytes, DC-derived from
these monocytes, hematopoietin-treated CD34+ cells and DC-
derived from these CD34+ cells. CD4+ and CD8+ T cells activated
with PHA were also tested. Control ampli®cations (actin) are also
shown. (B) BAFF mRNA was detected in T cell clones (TCC). (C)
Circulating DC were puri®ed from blood cells harboring a high
forward scatter and a low level of CD4 expression (R1). These cells
were further selected based on the expression of MHC class II with
an absence of expression of CD3, CD14, CD16 and CD19 (R2).
BAFF and control GAPDH mRNA were detected in these blood DC
by RT-PCR.
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experiments show that BAFF mRNA is expressed in DC and
their precursors, and at a lower level in T cells.
We next studied BAFF at the protein level. The BAFF protein
contains a transmembrane domain and a cleavage site for
furin-like proteases in its extracellular portion. We failed to
detect surface expression of BAFF in T cells as well as in DC,
despite the fact that the four different mAbs and the
recombinant soluble receptors (TACI±Ig and BCMA±Ig)
used in FACS analyses ef®ciently stained 293T cells trans-
fected with BAFF cDNA (data not shown). Total stainings after
cell permeabilization did not allow us to detect BAFF expres-
sion by ¯ow cytometry (data not shown), indicating that the
expression level of cell-associated BAFF is below the detec-
tion limit of the reagents used with cyto¯uorimetric analysis.
We next analyzed cell lysates by western blot. In these
experiments, the mAb Buffy-2 was used to detect BAFF
protein. The speci®city of Buffy-2 was ®rst demonstrated on
293T cells transiently transfected with BAFF. Buffy-2 recog-
nized a triplet of bands at ~35 kDa, likely to correspond to
various glycosylation isoforms of full-length BAFF (Fig. 2A,
left). Mock-transfected 293T cells did not give any reactivity.
With this method, endogenous full-length BAFF protein was
observed in activated T cells and DC as a single 35-kDa band,
while no reactivity was observed with B cells (Fig. 2A, right).
The size of full-length BAFF is in agreement with the predicted
mol. wt of 35 kDa. This analysis indicates that BAFF protein is
detected in T cells and DC. We next looked for BAFF secretion.
For this purpose, BAFF was immunoprecipitated with BCMA±
Ig from cell supernatants and analyzed by western blot with
the CT anti-BAFF serum. The CT anti-BAFF antibody was not
used previously on cell lysates due to the presence of a cross-
reactive band at ~30 kDa observed with this antibody. BAFF
immunoprecipitation with BCMA±Ig and detection with the CT
anti-serum was ®rst validated with secreted proteins from
transfected cell supernatants (Fig. 2B, left panel).
Immunoprecipitation of 1 ml of medium conditioned for 2
days by 106 DC allowed the resolution of a faint 18-kDa band
for BAFF (Fig. 2B, left). The size of secreted BAFF is in
reasonable agreement with the predicted mol. wt of 18 kDa for
cleaved BAFF. Under similar conditions, BAFF was not
detected in supernatants of activated T cells. According to
the faint band obtained with DC supernatant and the lower
expression level of BAFF in T cells, the absence of detectable
secreted BAFF in T cell supernatants is most likely due to a
sensitivity problem in the assay used. The apparent size of 18
kDa for cleaved BAFF, both for the transfected and the
endogenously expressed protein, indicates that the glycosy-
Fig. 2. DC secrete BAFF. (A) Lysates from 0.02 3 106 transfected
293T cells (left panel) or 0.2 3 106 leukocytes (right panel) were
analyzed by western blot. BAFF protein was detected with the Buffy-
2 mAb. Right panel shows full-length BAFF (35 kDa) in activated T
cells (anti-CD3 and anti-CD28 for 48 h) and DC. (B) Supernatants of
transfected 293T cells (left panel) or the indicated leukocytes (right
panel) were immunoprecipitated with BCMA±Ig and analyzed by
western blot. BAFF protein was detected with the CT anti-BAFF
antibody. Soluble BAFF recovered from DC supernatants migrated
at 18 kDa.
Fig. 3. BAFF expression is up-regulated following TCR±CD3
triggering. Puri®ed T cells were stimulated with coated anti-CD3 with
or without co-stimulatory signals (anti-CD28 or BAFF) and total RNA
subjected to RT-PCR analysis. (A) Semi-quantitative analysis after
35 cycles of standard RT-PCR. Actin transcription was monitored as
a control. Similar results were obtained with T cells puri®ed from a
second donor. (B) Total RNA was extracted after 18 h of stimulation
and subjected to real-time PCR analysis of BAFF mRNA. Results are
expressed in arbitrary units of mRNA. A similar result was obtained
with T cells puri®ed from a second donor.
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lation site in this domain is not used, consistent with previous
observations (1).
BAFF is up-regulated following cellular activation
To further document BAFF expression in leukocytes, we
studied the regulation of BAFF expression upon cellular
activation. In T cells, semi-quantitative RT-PCR analysis
indicated that BAFF mRNA appears up-regulated upon
TCR±CD3 stimulation and that this up-regulated mRNA
could be detected up to 3 days following stimulation
(Fig. 3A). Further analyses with quantitative real-time PCR
showed that T cell stimulation by an anti-CD3 antibody
induced a 10-fold increase in BAFF mRNA (Fig. 3B). This
increase was evident when RNA was extracted 18 h following
stimulation, but was not yet observed after 4 h (data not
shown). Addition of a co-stimulatory signal with an anti-CD28
antibody or with BAFF itself did not in¯uence the levels of BAFF
mRNA (Fig. 3B), even when a suboptimal concentration of
anti-CD3 antibody was used (data not shown). Co-stimulation
signals in the absence of anti-CD3 did not modulate BAFF
mRNA (Fig. 3B). Altogether, these data show that BAFF
expression is markedly increased when T cells are stimulated
through their TCR in a co-stimulation-independent manner.
In DC, we observed that exposure to the bacterial products,
LPS or LTA, for 18 h resulted in a 3-fold up-regulation of BAFF
mRNA (Fig. 4). On the contrary, other DC maturating agents
belonging to the TNF family, such as TNF or CD40L, failed to
up-regulate BAFF mRNA. In this experiment, IFN-g treatment
also up-regulated BAFF mRNA in a similar range as previously
reported (13). Similar up-regulation was also observed 4 h
after LPS stimulation (data not shown). A comparison between
the quantitative RT-PCR analyses performed on DC and T
cells indicated that resting and activated T cells express only
0.3±1 and 3±10% respectively of the BAFF mRNA found in DC.
These experiments show that BAFF is constitutively expressed
in DC and that DC stimulation with bacterial products or IFN-g
induces an up-regulation of BAFF expression.
Production of endogenous BAFF provides T cell co-
stimulation
Since recombinant BAFF provides T cell co-stimulation, we
tested whether blockade of endogenous BAFF could modu-
late T cell activation. We ®rst performed an anti-CD3-driven T
cell proliferation assay with puri®ed T cells. In this experiment,
addition of a BAFF antagonist, TACI±Ig, resulted in a 2-fold
inhibition of the T cell proliferation (Fig. 5A). In this anti-CD3
stimulation of puri®ed T cells, addition of an anti-CD28
increases the cellular proliferation, indicating the dependence
for co-stimulation in this stimulation assay. The presence of
contaminating APC that could have provided a source of BAFF
is therefore unlikely in this assay. In a second experiment, we
used total PBMC wherein circulating APC represents another
source of BAFF. When these total PBMC were stimulated with
the anti-CD3 antibody, addition of TACI±Ig at 50 mg/ml
resulted in an almost complete inhibition of the T cell
proliferation for 0.01 and 0.1 mg/ml of anti-CD3 (Fig. 5B). For
1 mg/ml of anti-CD3, TACI±Ig inhibition was bypassed. No
inhibition was seen with the control huIgG1. Since huIgG1 may
not be the best negative control, we also used in this
experiment Fn14±Ig as an irrelevant TNF receptor fused to
the constant region of huIgG1. No inhibition was observed in
the presence of 50 mg/ml of Fn14±Ig (data not shown). In this
assay using unseparated PBMC, the proliferation observed
was mediated by T cells and was dependent on co-stimulation
provided by APC. Indeed, B cell depletion (CD19+ fraction)
had no effect and APC removal (CD14+ or MHC class II+
fraction) resulted in a strong inhibition (data not shown). TACI
binds two ligands in the TNF superfamily, BAFF and APRIL
(19,20). In addition to BAFF, monocytes and monocyte-
derived DC expressed APRIL mRNA (Fig. 5C). However, the
pattern of expression is dissimilar in other cell types, since
APRIL mRNA is not expressed in T cells, resting or activated
(Fig. 5C, higher panel). This APRIL pattern of expression was
con®rmed at the protein level. Secreted APRIL was recovered
upon immunoprecipitation of 5 ml of supernatant conditioned
by monocyte or monocyte-derived DC at 0.2 3 106/ml for 4
days, but was absent from supernatant conditioned for 4 days
by B or T cells at 1 3 106/ml (Fig. 5C, lower panel). In this
experiment, endogenous APRIL secreted from monocyte-
derived DC resolved as a double band at ~22 kDa. A longer
exposure time of the western blot also revealed a double band
in the supernatant derived from monocytes (data not shown).
The 22-kDa size is consistent with the predicted mol. wt of 16
kDa without glycosylation for secreted APRIL. The apparent
double band could be due to different glycosylation patterns
or to recovery in the immunoprecipitate of the two different
APRIL isoforms a (accession no. NM 03808) and b (accession
no. NM 172087) that differ by 16 internal amino acids. It is
unlikely that the existence of two bands is due to the presence
in the immunoprecipitate of the hybrid TWE-PRIL molecule
generated by intergenic splicing between TWEAK and APRIL
(21) or to heterodimeric BAFF/APRIL molecules (22), since the
double band is also observed with 293T transfected with
APRIL in the absence of TWEAK or BAFF (recovered from 1 ml
supernatant conditioned for 4 days with transfected 293T cells
at 0.1 3 106/ml) (Fig. 5C). Altogether, this analysis demon-
strates that APC express two TACI ligands, BAFF and APRIL.
Fig. 4. BAFF expression is up-regulated upon DC maturation with
bacterial products. DC differentiated from monocytes were treated
with LPS (20 ng/ml), LTA (10 mg/ml), TNF (10 ng/ml), soluble CD40L
(100 ng/ml) or IFN-g (500 UI/ml) for 18 h. Total RNA was extracted
and subjected to real-time RT-PCR analysis as in Fig. 3. A similar
result was obtained with DC from a second donor.
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On the contrary, T cells express only BAFF. In order to identify
the TACI ligand produced by APC and involved in T cell co-
stimulation, we used BAFF-R±Ig showing a strict speci®city for
BAFF in the TNF family (23,24). BAFF-R±Ig blocked the T cell
proliferation obtained (Fig. 5D). The slight difference in the
inhibition obtained here with BAFF-R±Ig and TACI±Ig is not
conclusive, since we used the murine form of BAFF receptor
and the human form of TACI. To formally demonstrate that
Fig. 5. Soluble TACI and BAFFR inhibit anti-CD3-driven T cell proliferation. (A) Puri®ed T cells (1 3 105) were activated with coated anti-CD3
at 1 mg/ml for 72 h. huTACI±Ig and huIgG1 (control Ig) were used at 50 mg/ml. Anti-CD28 was used at 100 ng/ml. The results are expressed
as the mean thymidine incorporation from triplicate cultures 6 SD. Background proliferation in the absence of anti-CD3 was 500 6 50 c.p.m.
(B) PBMC (1 3 105) were activated with increasing concentrations of coated anti-CD3. The proliferation obtained in the presence of medium
alone, huTACI±Ig (50 mg/ml) or huIgG1 (cIg, 50 mg/ml) is shown. Similar results were observed with PBMC from six independent donors. (C)
RNA from the indicated cell subsets were extracted and subjected to RT-PCR (40 cycles) with an APRIL-speci®c primer pair. Upper panel
shows APRIL mRNA expression in monocytes, DC derived from monocytes, and absence of expression in B and T cells. Control actin
ampli®cation is also shown. Cell supernatants from the indicated cells were immunoprecipitated with BCMA±Ig and APRIL expression was
studied in western blot analysis with the aprily-1 mAb. Soluble APRIL recovered from cell supernatants migrated as a double band of 22 kDa.
(D) PBMC (1 3 105) were activated with coated anti-CD3 at 0.1 mg/ml. The proliferation obtained in medium alone or in the presence of
increasing concentration of muBAFF-R±Ig, huTACI±Ig or control Ig (huIgG1) is shown. Background proliferation in the absence of anti-CD3
was 5200 6 260 c.p.m. Similar results were obtained with three independent donors. (E) Puri®ed T cells (1 3 105) were activated with coated
anti-CD3 at 0.1 mg/ml in the presence of 1 3 104 autologous puri®ed monocytes. TACI±Ig and control Ig (huIgG1) were used at 15 mg/ml.
Background proliferation in the absence of anti-CD3 was 340 6 54 c.p.m. Similar results were observed in a repeat experiment.
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circulating APC provide BAFF co-stimulation to T cells, we
activated puri®ed T cells with coated anti-CD3 in the presence
of puri®ed autologous monocytes. The presence of TACI±Ig
resulted in an almost complete inhibition of the anti-CD3-
driven proliferation, while no effect was seen with control Ig
(Fig. 5E). Altogether, this demonstrates that BAFF produced
by APC and, to a lesser extent, by T cells themselves provides
co-stimulation to anti-CD3 stimulation of T cells.
Discussion
In the present study, we characterized the expression of the
TNF ligand BAFF in subsets of human leukocytes and
analyzed its T cell co-stimulatory activity. At the RNA level,
we found expression of BAFF in APC. Indeed, ex vivo blood
DC and DC derived from monocytes or CD34+ stem cells
express abundant levels of BAFF mRNA. We observed also
BAFF expression in cells that are known to give rise to DC,
CD34+ stem cells expanded in vitro with a hematopoietin
cocktail (25,26) and peripheral blood circulating monocytes
(27,28). This indicates that BAFF expression is already
initiated at the DC precursor stage. A low level of BAFF
expression, up-regulated ~10-fold upon TCR±CD3 stimula-
tion, was observed in T cells. The up-regulation of BAFF mRNA
in T cells upon TCR±CD3 stimulation is consistent with the up-
regulation previously observed with PHA stimulation (1). In
DC, BAFF mRNA is highly expressed compared to T cells
(100- to 300-fold more than in resting T cells), and BAFF
expression is further up-regulated upon maturation with
bacterial products such as LPS and LTA. Our results are in
agreement with the expression of BAFF described in myeloid
cells (1,2,13,14). On the contrary, BAFF expression in T cells is
controversial to date (1,2,13). In this study, we detected BAFF
message in T cell RNA with two independent sets of primers
and BAFF protein in T cell lysates. The failure to detect BAFF
gene expression in T cells by others is likely due to the lower
expression level in these cells compared to myeloid cells.
Overexpression experiments have demonstrated that cleav-
age of BAFF occurs at its furin recognition site (1,3). Our
results strongly suggests that this site is also used in primary
cells naturally expressing BAFF, such as DC. This is in
agreement with the processing described at this furin site for
transformed myeloid cells (13) and consistent with detection of
BAFF in the sera of patients with autoimmune diseases
(29,30). We did not detect BAFF secretion in T cells. This is
likely due to the lower expression level of this molecule rather
than an absence of BAFF cleavage in T cells. Indeed,
biochemical studies with a furin synthetic substrate as
described by Leitlein et al. (31) indicate the presence of
functional furin(s) in cellular lysates from activated T cells (data
not shown). These studies con®rm that DC produced and
released BAFF protein.
We previously demonstrated that recombinant BAFF co-
stimulates T cells (7). It was important to test whether
endogenous expression of BAFF triggers this biological effect.
In an anti-CD3 T cell stimulation assay using puri®ed T cells or
unseparated PBMC, the BAFF antagonist TACI±Ig signi®cantly
blocked T cell activation, especially when unseparated PBMC
where used. This result is concordant with the inhibition
obtained with TACI±Ig by Wang et al. in a similar assay with
murine splenocytes cells (11). Since we did not observe any
detectable APRIL (the second TNF ligand binding to TACI)
expression in T cells, this indicates that endogenous BAFF co-
stimulates T cells in an autocrine fashion. Contrary to T cells,
we observed that APRIL is co-expressed with BAFF in APC,
consistent with previous reports (21,32,33). The inhibition
observed in our experiments with soluble BAFF-R identi®es
BAFF as the TACI ligand produced by APC and providing T
cell co-stimulation. The almost complete inhibition obtained
with BAFF-R±Ig in this experiment indicates that BAFF is
mandatory for this co-stimulation pathway. We do not ®nd any
evidence indicating a role for APRIL in this T cell activation
assay.
To date, three receptors have been described for BAFF:
BAFF receptor (or BR3) (23,24), BCMA and TACI (19,20,34).
BAFF receptor and TACI have been previously reported
expressed in T cells (23,35). The recently described pro-
apoptotic signaling property described for TACI in B cells (36)
is an argument against a T cell co-stimulatory activity for this
receptor. BAFF receptor may therefore be the receptor
involved in the T cell co-stimulation pathway described here.
Additional experiments are needed to clarify this issue. The
results presented here indicate that BAFF, in addition to its B
cell stimulatory activity, also provides T cell co-stimulation. Its
high expression in APC that can be up-regulated upon
maturation indicates that BAFF may act preferentially when
professional APC present an antigen to T cells. Its lower
expression in T cells indicates that BAFF may also act in an
autocrine fashion.
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BAFF B cell-activating factor from the TNF family
BCMA B cell maturation antigen
GM-CSF granulocyte macrophage colony stimulating factor
LTA lipoteichoic acid
LPS lipopolysaccharide
PBMC peripheral blood mononuclear cell
PHA phytohemagglutinin
TACI transmembrane activator and CAML interactor
TNF tumor necrosis factor
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